Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The phase 2 MAHALO clinical trial shows that lampalizumab reduces geographic atrophy secondary to age-related macular degeneration and implicates complement dysregulation in disease pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
Self-citationComplement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Because there is risk without potential benefit with a placebo intravitreal injection, sham injections have served as the acceptable control for study drug injections (29, 30).”
BackgroundFast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894 · cited 1×
“The reads that passed were then aligned to the reference genome GRCh37 using gsnap (34).”
MethodSeven new loci associated with age-related macular degeneration
The AMD Gene Consortium (2013) · Nature Genetics · doi:10.1038/ng.2578 · Cited by 788
Holz, F. G., Bindewald-Wittich, A., Fleckenstein, M., Dreyhaupt, J., Scholl, H. P. N., & Schmitz-Valckenberg, S. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.041 · Cited by 619
Self-citationMechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382 · cited 3×
“The prevalence of these risk alleles in the MAHALO study is consistent with other reports of risk-allele frequency in bilateral geographic atrophy cases (6) (table S3).”
BackgroundResultInfluentialSelf-citation
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561
Self-citationThe renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Holz, F. G., Sadda, S. R., Busbee, B., Chew, E. Y., Mitchell, P., Tufail, A., Brittain, C., Ferrara, D., Gray, S., Honigberg, L., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1544 · Cited by 354
Self-citationMicroglia in the Retina: Roles in Development, Maturity, and Disease
Silverman, S. M., & Wong, W. T. (2018) · Annual Review of Vision Science · doi:10.1146/annurev-vision-091517-034425 · Cited by 346
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
The challenges and promise of complement therapeutics for ocular diseases
Park, D. H., Connor, K. M., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01007 · Cited by 108
Clark, S. J., McHarg, S., Tilakaratna, V., Brace, N., & Bishop, P. N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01778 · Cited by 71
“One such therapeutic is lampalizumab, an anti-FD Fab fragment which is currently undergoing two phase III clinical trials for geographic atrophy (NCT02247479 and NCT02247531) after positive outcomes in a phase II trial (31).”
BackgroundGenetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Patel, P. J., Ziemssen, F., Ng, E., Muthutantri, A., Silverman, D., Tschosik, E. A., & Cantrell, R. A. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s226425 · Cited by 61
“The poorer function seen in patients in our study is despite the greater GA severity in the Mahalo population; patients recruited into Mahalo had to have a GA lesion size of ~1–7 DA at baseline, whereas 21% of worse-seeing eyes in our study had GA lesions of <1 DA.(27) These differences may be in part due to differenc…”
ResultInfluentialComplement inhibitors for age-related macular degeneration
Tzoumas, N., Riding, G., Williams, M. A., & Steel, D. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009300.pub3 · Cited by 38
Tzoumas, N., Hallam, D., Harris, C. L., Lako, M., Kavanagh, D., & Steel, D. H. W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.10.008 · Cited by 33
Therapeutic targeting of the complement system in ocular disease
Rathi, S., Hasan, R., Ueffing, M., & Clark, S. J. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103757 · Cited by 24
Annamalai, B., Parsons, N., Nicholson, C., Obert, E., Jones, B., & Rohrer, B. (2021) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.62.4.11 · Cited by 16
Wei, Y., Liao, H., & Ye, J. (2018) · Medicine · doi:10.1097/md.0000000000010422 · Cited by 13
Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration
Lin, J. B., Serghiou, S., Miller, J. W., & Vavvas, D. G. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100118 · Cited by 9
Metadata
- Authors
- Yaspan, B. L., Williams, D. F., Holz, F. G., Regillo, C. D., Li, Z., Dressen, A., van Lookeren Campagne, M., Le, K. N., Graham, R. R., Beres, T., Bhangale, T. R., Honigberg, L. A., Smith, A., Henry, E. C., Ho, C., Strauss, E. C., & for the MAHALO Study Investigators
- Venue
- Science Translational Medicine
- Published
- 2017-06-21
- Volume
- 9
- Issue
- 395
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2672043438
- Cited by
- 186
- References
- 9
- FWCI
- 21.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.